Prognostic clinical and radiographic biomarkers for BRAF targeted therapy in advanced melanoma.

Prognostic clinical and radiographic biomarkers for BRAF targeted therapy in advanced melanoma. Oncologist. 2020 Oct 12;: Authors: Shah KP, Song H, Ye F, Johnson DB Abstract Agents blocking BRAF and MEK produce robust responses in patients with BRAFV600 mutated melanoma, however more accurate clinical biomarkers are needed to predict prognosis. To explore this question, we retrospectively studied 158 patients with BRAF-mutated melanoma treated with BRAF +/- MEK inhibitors. We found that the number of distinct tumor sites upon initiation of targeted therapy is associated with decreased progression-free survival but had no effect on overall survival. Serum values of LDH and ALC/ANC ratio independently had the strongest association with both progression-free survival and overall survival. Using both of these markers can help stratify prognosis of patients with metastatic melanoma receiving targeted therapy. PMID: 33044751 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research